@entity1370 is the second leading cause of morbidity and mortality in @entity5 survivors. The objective of this international cardiac oncology survey was to gain a better understanding of current knowledge and practice patterns among HCPs involved in the management of @entity5 @entity1 exposed to potentially @entity1370 drugs. Between 2012 and 2013, we conducted an email-based survey of HCPs involved in the management of @entity299 in @entity5 @entity1 . 393 survey responses were received, of which 77 were from Canadian respondents. The majority of respondents were cardiologists (47%), followed closely by medical oncologists. The majority of respondents agreed that cardiac issues are important to @entity5 @entity1 (97%). However, only 36% of total respondents agreed with an accepted definition of @entity1370 . While 78% of respondents felt that cardiac medications are protective during active @entity5 treatment, only 51% would consider prescribing these medications up-front in @entity5 @entity1 . Although results confirm a high level of concern for cardiac safety, there continues to be a lack of consensus on the definition of @entity1370 and a discrepancy in clinical practice between cardiologists and oncologists. These differences in opinion require resolution through more effective research collaboration and formulation of evidence-based guidelines.

An International Survey of Health Care Providers Involved in the Management of Cancer @entity1 Exposed to XXXX Therapy.

@entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity1370 :: ('MESH:D066126', 'Disease') :: ['Cardiotoxicity', 'cardiotoxic', 'cardiotoxicity'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac disease']
@entity1370 :: (MESH:D066126,Disease) :: ['Cardiotoxic']
